190 filings
Page 7 of 10
6-K
IMAB
I-Mab
8 Feb 21
Proposed Registered Secondary Public Offering of
12:00am
424B5
IMAB
I-Mab
5 Feb 21
Prospectus supplement for primary offering
5:13pm
F-3ASR
IMAB
I-Mab
5 Feb 21
Automatic shelf registration (foreign)
4:47pm
6-K
IMAB
I-Mab
5 Feb 21
Index to Consolidated Financial Statements
4:21pm
424B5
IMAB
I-Mab
5 Feb 21
Prospectus supplement for primary offering
8:17am
6-K
IMAB
I-Mab
5 Feb 21
I-Mab Announces Multiple Clinical Advancements of its Differentiated CD73
8:11am
SC 13G
Fortune Eight Jogging Ltd
4 Feb 21
I-Mab / Fortune Eight Jogging ownership change
7:41am
SC 13D/A
Hillhouse Capital Advisors, LTD.
21 Dec 20
I-Mab / HILLHOUSE CAPITAL ADVISORS ownership change
4:05pm
EFFECT
IMAB
I-Mab
15 Dec 20
Notice of effectiveness
12:15am
CORRESP
IMAB
I-Mab
10 Dec 20
Correspondence with SEC
12:00am
UPLOAD
IMAB
I-Mab
9 Dec 20
Letter from SEC
12:00am
F-1
IMAB
I-Mab
1 Dec 20
Registration statement (foreign)
4:06pm
CORRESP
IMAB
I-Mab
1 Dec 20
Correspondence with SEC
12:00am
6-K
IMAB
I-Mab
13 Nov 20
Current report (foreign)
4:02pm
6-K
IMAB
I-Mab
12 Nov 20
I-Mab Announces Preclinical Data on Differentiated Anti-C5aR Antibody
6:06am
6-K
IMAB
I-Mab
10 Nov 20
I-Mab Reports Phase 1 Clinical Trial Data of Highly Differentiated Anti-CD47 Monoclonal Antibody Lemzoparlimab at the 2020 SITC Annual Meeting
6:19am
6-K
IMAB
I-Mab
5 Oct 20
I-Mab Receives China CDE Approval to Initiate Phase 3 Clinical Trial of
6:04am
6-K
IMAB
I-Mab
22 Sep 20
I-Mab Announces China NMPA Clearance for Phase 1 Clinical Trial of Lemzoparlimab in Relapsed or Refractory Advanced Lymphoma
6:05am
SC 13G
IMAB
I-Mab
21 Sep 20
I-Mab / GIC Private ownership change
4:08pm
6-K
IMAB
I-Mab
17 Sep 20
MorphoSys and I-Mab Announce FDA Clearance of IND Application for MOR210/TJ210 in Patients with Advanced Cancer
4:04pm